Abstract 3184
Background
REG is an active drug in non-adipocytic soft tissue sarcoma previously treated with doxorubicin (Mir et al. Lancet Oncol 2016). Efficacy of REG in PAZ pretreated pts is unknown. REGOSARC is a multi-cohort double-blind placebo (PLAC)-controlled phase II trial assessing the activity of REG in soft-tissue sarcoma previously treated with doxorubicin. Cross-over after centrally confirmed disease progression was allowed.
Methods
In the present subgroup analyses of the pooled study (cohorts B,C,D and E), we analyzed the magnitude of REG activity in pts with prior exposure to PAZ.
Results
The total study population consisted of 176 pts (101 women, 57%), with a median age of 59 (20-81). with the following histologies (n/%): leiomyosarcoma (80/45), synovial sarcoma (28/16) or other sarcoma (68/39). Most pts had PS = 0 (N = 83, 47%) or PS = 1 (N = 92, 52%). Median time from initial diagnosis to study enrollment was 30 months (range, 5.6-498). Median follow-up was 59.6 months. 88 pts each were allocated to the REG and placebo (PLAC) arms, including 21 (24%) and 22 (25%) pts with previous PAZ exposure. Overall, the significant benefit of REG compared to PLAC in terms of PFS with a median PFS of 3.8 (REG) vs 1.0 months (PLAC); HR(REG/PLAC)=0.43 [95%CI: 0.32-0.59], p<.00001, was confirmed. The magnitude of the benefit did not significantly differ when assessed by prior PAZ exposure: HR(REG/PLAC)=0.33 [0.18-0.61] for those previously exposed to PAZ and 0.45 [0.32-0.65] for those not exposed to PAZ; interaction test in Cox model, p = 0.35. In the total study population non significant numerically higher median OS was observed in the REG arm:13.4 (REG) vs 9.0 months (PLAC), HR = 0.76 [0.56-1.03], p = 0.08. The magnitude of this difference was larger in pts previously exposed to PAZ: HR(REG/PLAC)=0.43 [0.22-0.85] (p = 0.015), vs HR = 0.88 [0.62-1.25] (p = 0.49) for those not exposed to PAZ; interaction test, p = 0.065. Safety has been previously reported (Mir et al. Lancet Oncol 2016; Penel ASCO 2019).
Conclusions
We conclude that prior exposure to PAZ did not significantly modify PFS advantage of REG. Benefit of REG in terms of OS could be larger in patients previously exposed to PAZ.
Clinical trial identification
NCT01900743.
Editorial acknowledgement
Legal entity responsible for the study
Centre Oscar Lambret, Lille, France.
Funding
Bayer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5344 - Global trends in population-based survival for 303,169 adults diagnosed with glioblastoma in 44 countries during 2000-2014 (CONCORD-3)
Presenter: Fabio Girardi
Session: Poster Display session 1
Resources:
Abstract
3088 - Spanish Survey of treatment recommendations for elderley patients with glioblastoma
Presenter: María Ángeles Vaz Salgado
Session: Poster Display session 1
Resources:
Abstract
3484 - Updated analysis of the National Registry of Nervous System Tumors in Spain (RETSINE). RETSINE: National Registry of Nervous System Tumors of the Spanish Research Group in Neuro-oncology (GEINO) and Spanish Infrequent and Orphan Tumors Group (GETHI)
Presenter: Isaac Ceballos Lenza
Session: Poster Display session 1
Resources:
Abstract
4737 - Development and validation of novel nomograms predicting survival of malignant ependymoma patients: A population-based study
Presenter: Alzhraa Abbas
Session: Poster Display session 1
Resources:
Abstract
4740 - Characteristics, incidence, and survival of primary cerebral lymphoma: A population based study
Presenter: Sherief Ghozy
Session: Poster Display session 1
Resources:
Abstract
5362 - Trends in Incidence and Survival Analyses of Adult-onset Medulloblastoma
Presenter: Feifei Lin
Session: Poster Display session 1
Resources:
Abstract
3868 - Meta of classical chemotherapy compared with high-dose chemotherapy combined with autologous stem cell transplantation in newly diagnosed medulloblastoma patients after radiotherapy
Presenter: Mengting Zhang
Session: Poster Display session 1
Resources:
Abstract
4446 - Effect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumors: a single institution analysis
Presenter: Marta Nerone
Session: Poster Display session 1
Resources:
Abstract
5119 - Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases
Presenter: Angelika Starzer
Session: Poster Display session 1
Resources:
Abstract
3882 - Venous Thromboembolism and Intracranial Hemorrhage in Patients with High-grade Glioma
Presenter: Clara Borges
Session: Poster Display session 1
Resources:
Abstract